di-amidobenzimidazole STING agonists (GSK)

N/A

Report date: 2025/01/26 19:00:19

NME

Base Information

Drug Namedi-amidobenzimidazole STING agonists (GSK)

Drug Alias Namedi-amidobenzimidazole STING agonists (GlaxoSmithKline)di-amidobenzimidazole STING agonists (GlaxoSmithKline)diABZIdiABZI STING agonists (GlaxoSmithKline)amidobenzimidazole STING agonist (GlaxoSmithKline) +[6]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionStimulator of interferon genes stimulants

TargetsStimulator of interferon genes

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A